The clinical encounter is not a two-party relationship. There is a third presence in the room, composed of malpractice precedent, DEA scrutiny, prior-authorization architecture, board-of-medicine expectations, and institutional risk management. It does not speak. It shapes what can be offered, what can be discussed openly, and what stays outside the bounds of the conversation. The patient senses it. The prescriber feels it more acutely.
Flanigan directs her critique at the state, as if the state were a discrete actor whose policies could be evaluated on their merits and replaced with better ones. The state is not in the room. Individual prescribers are in the room, and the policies of the state arrive there refracted through professional liability, employer policy, payer requirements, and the residue of every malpractice case any of us has read about. What looks like medical paternalism is, in many cases, professional survival adapting to a system in which the visible costs of one kind of error are concentrated and the visible costs of the other are dispersed.
The cost of error is asymmetrically distributed. A patient who refuses care and deteriorates is generally respected as having exercised autonomy; the death is sad, but it is hers. A prescriber who provides risky access and watches harm follow is scrutinized, second-guessed, sometimes sued, occasionally disciplined by their state medical board. These outcomes are not philosophically symmetric, and prescribers have absorbed that asymmetry into their reflexes. Daniel Carpenter, in his analysis of the FDA in
Reputation and Power, names the same pattern at the regulatory scale: visible harms are minimized, dispersed harms are tolerated, and the institution's incentive structure runs in one direction. The clinic operates on the same logic as the agency, scaled to a single examination room.
There is something genuinely appealing to me about Flanigan's proposal from inside this structure. If physicians are not the gatekeepers, they are not the bearers of the consequences. The consultant role, in which I inform rather than authorize, is the more honest description of what I am actually competent to do. It removes a distortion in the encounter that the current regulatory structure quietly imposes. I would, in some moods, sign on tomorrow.
The cost of removing it is that gatekeeping organizes responsibility in ways that are not always coercive. The patient who can be conditionally offered a risky medication, contingent on a safety plan and a follow-up visit, is in a different conversation than the patient who can simply buy it at retail. Whether that difference is therapeutic or merely bureaucratic depends on the case, the patient, and the medication; the honest answer is that it is both, in proportions that vary.
Quong's distinction returns here in a form Flanigan does not fully address. Removing physician gatekeeping does not eliminate the coercive structure around pharmaceutical decisions. It relocates it. Insurers, employers, licensing bodies, fitness-for-duty examiners, family courts, child-welfare agencies: these are the secondary gatekeepers waiting to absorb the function. A pilot whose airline learns he has been self-medicating does not become more autonomous because his prescriber is no longer the bottleneck. Flanigan's payment proposals, which include collective insurance bargaining, conditional reimbursement, and vouchers, are sensible on their own terms, but they describe a system in which insurers retain decisive control over which drugs are practically affordable, and that control is itself a form of gatekeeping.
Her reform of the prescription system would not abolish gatekeeping. It would migrate it from a clinical relationship, where there is at least some individual accountability and some possibility of negotiation, into administrative structures with less of either.
VI. What the Book Gets Uncomfortably Right
This is where Flanigan's abstraction becomes clinically useful. There is a version of her argument that sounds exaggerated until you follow it through the structure described above. Delay accumulates in individual patients. In aggregate it looks like a policy. In the clinic it looks like a pattern.
Four things in the book survive clinical scrutiny better than I would like them to.
The first is that delay is a body count, and the count is not zero. Flanigan's most provocative line, the one about prescription requirements killing people, lands harder here than in the section that introduced it, because by now the reader has the structure to see what she means. The sequence is familiar to anyone who has watched a patient cycle through the standard-of-care options for a treatment-resistant condition. An early-phase signal is not strong enough to meet the chosen endpoint. The endpoint was chosen to withstand regulatory scrutiny rather than to register clinical benefit. The trial extends. Approval waits. The patient cycles through partial responses, accumulates side effects, loses jobs and relationships, and eventually either stabilizes on something inadequate or does not stabilize at all. The drug arrives later, with narrower labeling and higher evidentiary confidence. Some patients benefit. Others have already moved on, in one direction or another. No one counts the ones who did not wait.
This is the asymmetry Carpenter describes at institutional scale. The cost of being wrong in one direction is concentrated, identifiable, traceable to a decision; the cost of being wrong in the other direction is dispersed across a population that never appears in the same frame as the decision that produced it. That asymmetry constrains what I can offer the person sitting in front of me. The menu of available treatments at any given visit is a function of what is approved, what is labeled, what is defensible, and what is reimbursable. I am choosing among the survivors of a filtration process that selected for evidentiary confidence at the cost of timeliness, and for legal defensibility at the cost of clinical range. Flanigan is right that delay carries a cost. Carpenter explains why that cost is tolerated. The clinic is where the two positions meet and refuse to resolve.
The second is regulatory inconsistency. Alcohol is sold at gas stations. Tobacco is regulated at point of sale rather than at access. The supplement industry sells substances with measurable pharmacological effects under almost no oversight, some of which overlap meaningfully with prescription pharmacology. Meanwhile, drugs with established mechanisms, known dosing, decades of safety data, and clear therapeutic niches remain tightly controlled. The boundary does not track risk. It tracks regulatory history, which is to say it tracks the order in which different industries developed, captured their respective agencies, and stabilized their privileges.
The third is that restriction redistributes harm rather than eliminating it, and the redistribution is stratified by resources. The patients who already operate in a world of pharmaceutical freedom are overwhelmingly wealthy, educated, well-connected, and white. They have the time, language, money, and confidence to use international pharmacies, online vendors, supplement markets, ketamine-clinic networks, and direct-to-consumer telehealth. They self-experiment with peptides, pay cash for novel neuromodulation protocols, and design off-label regimens with help from physicians willing to advise them and from AI tools that explain pharmacokinetics on demand. One patient with bipolar disorder, able to afford a nonstandard neuromodulation course out of pocket, designed a variant protocol after reading the literature; it seems to have helped him, and the clinical work was free to proceed because he could bypass the insurance pathway entirely. Another patient, after years of severe fibromyalgia, researched a newly approved neurosteroid obsessively and had two weeks of striking relief on samples left at an office; her right-to-try appeal failed and she could not afford the cash price. What separated those two patients was resources rather than biology. Patients without those resources remain inside the formal system, where access is slower, narrower, and subject to authorization workflows designed by people who do not have to use them. Psychedelic therapy is the cleanest contemporary example: psilocybin retreats in legal jurisdictions, ketamine clinics, and underground guides are available to people who can afford them, while the same compounds remain federally inaccessible to the patients most likely to benefit and least likely to find a way around the prohibition.
The fourth is that restriction shapes honesty. This is essentially Anomaly's learned-helplessness point, and it deserves the most attention. When access depends on prescriber approval, the patient has a strong incentive to present in whatever way maximizes the likelihood of getting what they want. Symptoms are emphasized or hidden. Histories are edited. Substance use gets reframed as something else, or omitted. This is not lying in the sense that anyone would prosecute. It is adaptation to a system where the prescriber's authority over access creates a corresponding pressure on the information that prescribers receive. Anomaly's framing draws on Mill: state restrictions, by promising to manage risks on the citizen's behalf, can permanently stunt the development of the very faculties that would have allowed the citizen to manage them. The clinical version is more local. The frame that promises to protect the patient from bad decisions also produces the patient who cannot tell his doctor what he is actually doing.
A system that restricts access does not eliminate risk. It redistributes it: toward patients who cannot find their way around the workarounds, into clinical encounters where honesty has been priced out, and onto the timelines of patients waiting for permission that may never arrive. The conversation in which the options run out happens more often than the policy debate suggests.
VII. Toward a Capacity-Based Hybrid
The book's great virtue is that it forces clinicians to defend the gatekeeping role rather than assume it. Most pharmaceutical regulation is implicitly risk-based. The higher the perceived risk of a drug, the tighter the controls on access. Flanigan's most useful contribution, after the symmetry argument, is to demonstrate that risk on its own is a poor foundation for coercion; many activities of comparable or greater risk go entirely unrestricted, and the threshold at which paternalism becomes legitimate is not derived from any consistent principle.
A capacity-based framework offers a different organizing principle. The threshold for restricting access is not the level of risk involved, but the integrity of the decision-making process about that risk. [...]
The right analogy is not the prescriber as gatekeeper but the prescriber as fiduciary advisor. Financial advisors do not authorize their clients' trades; they cannot prevent a client from making a foolish investment. What they offer is a relationship across time, a track record of trust long enough to make persuasion possible, and the authority that comes from being someone the client has chosen to listen to. The advisor's job is to deepen the conditions under which the client can exercise autonomy well, not to override it. Having no coercive authority is what makes the advisor freer to be honest about what the client is doing wrong. That structural freedom is precisely what the prescriber's role currently lacks.
